Insulin production by engineered muscle cells

Human Gene Therapy

Volumn 10, Issue 7, 1999, Pages 1207-1217

  Gros, Laurent ^a   Riu, Efren ^a   Montoliu, Lluis ^a,b   Ontiveros, Maria ^a   Lebrigand, Laurence ^c   Bosch, Fatima ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOPROTEASE; FURIN; MESSENGER RNA; MYOSIN LIGHT CHAIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROINSULIN; PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERA; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSFECTION; GLUCOSE INTAKE; GLUCOSE UTILIZATION; HEPATOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERGLYCEMIA; INSULIN SYNTHESIS; INSULIN TREATMENT; INSULINEMIA; MOUSE; MUSCLE CELL; MYOTUBE; NONHUMAN; PROMOTER REGION; PROTEIN DEGRADATION;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSPLANTATION; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, EXPERIMENTAL; GENETIC ENGINEERING; GLUCOSE; GLYCOGEN; HUMANS; INSULIN; LACTATES; MICE; MICE, INBRED C3H; MUSCLES; MYOSIN LIGHT CHAINS; PROINSULIN; RATS; RNA, MESSENGER;

EID: 0033135207     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018193     Document Type: Article

References (37)

1. BARR, E., and LEIDEN, J.M. (1991). Systemic delivery of recombinant proteins by genetically modified myoblasts. Science 254, 1507-1509.
2. BINDER, C., LAURITZEN, T., FABER, O., and PRAMMING, S. (1984). Insulin pharmacokinetics. Diab. Care 7, 188-199.
3. BLAU, H.M., CHIU, C.-P., and WEBSTER, C. (1983). Cytoplasmic activation of human nuclear genes in stable heterocaryons. Cell 32, 1171-1180.
4. BREMS, D.N., BROWN, P.L., BRYANT, C., CHANCE, R.E., GREEN, L.K., LONG, H.B., MILLER, A.A., MILLICAN, R., SHIELDS, J.E., and FRANK, B.H. (1992). Improved insulin stability through amino acid substitution. Protein Eng. 5, 519-525.
5. CARROLL, R.J., HAMMER, R.E., CHAN, S.J., SWIFT, H.H., RUBENSTEIN, A.H., and STEINER, D.F. (1988). A mutant human proinsulin is secreted from islets of Langerhans in increased amounts via an unregulated pathway. Proc. Natl. Acad. Sci. U.S.A. 85, 8943-8947.
6. CHIRGWIN, J.M., PRZYBYLA, A.W., McDONALD, R.J., and RUTTER, W.J. (1979). Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18, 5294-5299.
7. CLARK, S.A., QUAADE, C., CONSTANDY, H., HANSEN, P., HALBAN, P., FERBER, S., NEWGARD, C.B., and NORMINGTON, K. (1997). Novel insulinoma cell line produced by iterative engineering of GLUT2, glucokinase, and human insulin expression. Diabetes 46, 958-967.
8. DAI, Y., ROMAN, M., NAVIAUX, R.K., and VERMA, I.M. (1992). Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo. Proc. Natl. Acad. Sci. U.S.A. 89, 10892-10895.
9. DEGLON, N., HEYD, B., TAN, S.A., JOSEPH, J.-M., ZURN, A.D., and AEBISHER, P. (1996). Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts. Hum. Gene Ther. 7, 2135-2146.
10. DHAWAN, J., PAN, L.C., PAVLATH, G.K., TRAVIS, M.A., LANCTOT, A.M., and BLAU, H.M. (1991). Systemic delivery of human growth hormone by injection of genetically enginerred myoblasts. Science 254, 1509-1512.
11. DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986.
12. DONOGHUE, M., ERNST, H., WENTWORTH, B., NADALGINARD, B., and ROSENTHAL, N. (1988). Muscle specific enhancer is located at the 3′ end of the niyosin light chain 1/3 gene locus. Genes Dev. 2, 1779-1790.
13. EFRAT, S., LEISER, M., SURANA, M., TAL, M., FUSCO, D.D., and FLEISCHER, N. (1993). Murine insulinoma cell line with normal glucose-regulated insulin secretion. Diabetes 42, 901-907.
14. FERBER, S., BELTRANDELRIO, H., JOHNSON, J.H., NOEL, R.J., CASSIDY, L.E., CLARK, S., BECKER, T.C., HUGHES, S.D., and NEWGARD, C.B. (1994). GLUT-2 gene transfer into insulinoma cells confers both low and high affinity glucose-stimulated insulin release. Relationship to glucokinase activity. J. Biol. Chem. 269, 11523-11529.
15. FERRE, T., RIU, E., BOSCH, F., and VALERA, A. (1996). Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J. 10, 1213-1218.
16. GRANNER, D., ANDREONE, T., SASAKl, K., and BEALE, E. (1983). Inhibition of transcription of the P-enolpyruvate carboxykinase gene by insulin. Nature (London) 305, 549-551.
17. GROS, L., MONTOLIU, L., RIU, E., LEBRIGAND, L., and BOSCH, F. (1997). Regulated production of insulin by non-β-cells. Hum. Gene Ther. 8, 2249-2259.
18. GROSKREUTZ, D.J., SLIWKOWSKI, M.X., and GORMAN, C.M. (1994). Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. J. Biol. Chem. 269, 6241-6245.
19. GROSS, D.J., HALBAN, P.A., KAHN, C.R., WEIR, G.C., and VILLAKOMAROFF, L. (1989). Partial diversion of a mutant proinsulin (BIO aspartic acid) from the regulated to the constitutive secretory pathway in transfected AtT-20 cells. Proc. Natl. Acad. Sci. U.S.A. 86, 4107-4111.
20. HEINE, R.J., BILO, H.J.K., and SIKENK, A.C. (1985). Mixing short and intermediate acting insulins in the syringe: Effects on the post-prandial blood glucose concentrations in type I diabetics. Biol. Med. J. 290, 204-205.
21. HOHMEIER, H.E., BELTRANDELRIO, H., CLARK, S.A., HENKELRIEGER, R., NORMINGTON, K., and NEWGARD, C.B. (1997). Regulation of insulin secretion from novel engineered insulinoma cell lines. Diabetes 46, 968-977.
22. KERVRAN, A., RIEUTORT, M., and GUILLAUME, M. (1976). A simultaneous radioimmunoassay for growth hormone and insulin in the plasma of rats and rabbits. Diabète Métabol. 2, 67-72.
23. KOLODRA, T.M., FINEGOLD, M., MOSS, L., and WOO, S.L.C. (1995). Gene therapy for diabetes mellitus in rats by hepatic expression of insulin. Proc. Natl. Acad. Sci. U.S.A. 92, 3293-3297.
24. RINSCH, C., REGULIER, E., DEGLON, N., DALLE, B., BEUZARD, Y., and AEBISCHER, P. (1997). A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum. Gene Ther. 8, 1881-1889.
25. RIU, E., BOSCH, F., and VALERA, A. (1996). Prevention of diabetic alteratins in transgenic mice overexpressing myc in the liver. Proc. Natl. Acad. Sci. U.S.A. 93, 2198-2202.
26. ROSENTHAL, N., KORNHAUSER, J.M., DONOGHUE, M., ROSEN, K.M., and MERLIE, J.P. (1989). Myosin light chain enhancer activates muscle-specific, developmentally regulated gene expression in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 86, 7780-7784.
27. ROSSINI, A.A., APEL, M.C., WILLIAMS, R.M., and LIKE, A.A. (1977). Genetic influence of the streptozotocin-induced insulitis and hyperglycemia. J. Am. Diab. Assoc. 26, 916-920.
28. RUDERMAN, N.B., WILLIAMSON, J.R., and BROWNLEE, M. (1992). Glucose and diabetic vascular disease. FASEB J. 6, 2905-2914.
29. SCHALKEN, J.A., ROEBROEK, A.J.M., OOMEN, P.P.C.A., WAGENAAR, S.S.C., DEDRUYNE, F.M.J., BLOMEMERS, H.P.J., and VAN DEN VEN, W.J.M. (1987). Furin expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. J. Clin. Invest. 80, 1545-1549.
30. SCHNEIDER, D.J., NORDT, T.K., and SOBEL, B.E. (1993). Attenuated fibrinolysis and accelerated artherogenesis in type II diabetic patients. Diabetes 42, 1-7.
31. SCHNEDL, W.J., FERBER, S., JOHNSON, J.H., and NEWGARD, C.B. (1994). STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 43, 1326-1333.
32. SIMONSON, G.D., GROSKREUTZ, D.J., GORMAN, C.M., and MACDONALD, M.J. (1996). Synthesis and processing of genetically modified human proinsulin by rat myoblast in primary cultures. Hum. Gene Ther. 7, 71-78.
33. VALERA, A., FILLAT, C., COSTA, C., SABATER, J., VISA, J., PUJOL, A., and BOSCH, F. (1994). Regulated expression of human insulin in the liver of transgenic mice corrects diabetics alterations. FASEB J. 8, 440-447.
34. SRF is expressed and required during myogenic differentiation of both mouse C2 and rat L6 muscle cell lines. J. Cell Biol. 118, 1489-1500.
35. WILLIAMSON, J.R., CHANG, K., FRANCOS, M., HASAN, K.S., IDO, Y., KAWAMURA, T., NYENGAARD, J.R., VAN DEN ENDEN, M., KILO, C., and TILTON, R.G. (1993). Hyperglycemic pseudo-hypoxia and diabetic complications. Diabetes 42, 801-813.
36. YAFFE, D., and SAXEL, O., (1977). Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature (London) 270, 725-727.
37. YANAGITA, M., HOSHINO, H., NAKAYAMA, K., and TAKEUCHI, T. (1993). Processing of mutated proinsulin with tetrabasic cleavage sites to mature insulin reflects the expression of furin in nonendocrine cell lines. Endocrinology 133, 639-644.